| Date | Title | Description |
| 20.01.2026 | Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry | Drug pricing, looming patent cliffs, dealmaking and the first year of the second Trump administration dominated conversations at the annual JPMorgan Healthcare Conference in San Francisco.
Top executives from drugmakers of all sizes met wit... |
| 12.09.2025 | Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground | Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year.
Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo’s oral semaglutide in the coming months, said Lilly’s Chief Sc... |
| 09.07.2025 | Norstella Appoints Kris Joshi as Chief Executive Officer | Norstella logo
Norstella, a leading global provider of pharma intelligence solutions, has appointed health-tech leader Kris Joshi as the company's new CEO. Previous CEO Mike Gallup will transition to the role of Executive Chairman.
NEW YORK... |
| 18.03.2025 | Norstella Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 | Global provider of pharma intelligence solutions joins the ranks of Waymo, Nvidia, Duolingo, and more
NEW YORK, March 18, 2025 /PRNewswire-PRWeb/ -- Norstella, a leading global provider of pharma intelligence solutions, is proud to have bee... |
| 03.01.2025 | Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open' | Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug candidates and the lives of people who work in biotech. Evaluate analysts made predictions in their 2025 preview—and any... |
| 19.12.2024 | The Shifting Sands of Pharma and Energy: Opportunities Amidst Uncertainty | In the world of finance, change is the only constant. Two sectors currently in the spotlight are pharmaceuticals and energy. Both face unique challenges and opportunities. Investors must navigate these shifting sands carefully.
Novo Nordisk... |
| 18.12.2024 | Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. |
Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: NVO). The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. Marketed th... |
| 08.01.2024 | This is the TLDR of JPM Day 1 | In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference, join our newsletter list.
“The lanyards” have landed! A... |
| 16.07.2023 | The Next Frontier For Large Language Models Is Biology | David Baker (University of Washington), Demis Hassabis (DeepMind) and George Church (Harvard) have ... [+] helped pioneer the field of AI-driven protein design.Photo source: U of W, Royal Society, Harvard |
| 10.05.2023 | 16 top healthcare bankers and dealmakers reveal their predictions for the future of digital health | Barclays; Lazard; Canaccord Genuity; General Atlantic; Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The digital-health sector in 2020 and 2021 was the hottest part of healthcar... |
| 14.03.2023 | The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq? | The latest fear stalking biotech boardrooms isn’t a trial fail or an underwhelming funding haul, it’s the postman delivering a letter from the Nasdaq warning that the company’s stock faces delisting from the stock exchange.
It seems to be a... |
| 03.03.2023 | Big Pharma regained 'mojo' last year, but biotech valuations remain 'precarious': report | Anyone looking for a road map out of the biotech bear market will take little comfort from Evaluate Vantage’s latest report. While Big Pharma valuations “regained their mojo” toward the end of last year, the outlook remains bleak for smalle... |
| 19.01.2023 | EQRx promised to deliver cutting-edge drugs at half the cost of rivals. A cofounder shares why the once buzzy biotech is walking away from that mission | EQRx cofounder and executive chairman Alexis Borisy EQRx This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
After years of touting the idea of radically lower drug prices, EQRx has walked aw... |
| 04.01.2023 | Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president | Brad Loncar, biotech investor and CEO of Loncar Investments Brad Loncar This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
For the third straight year with Insider, biotech investor Brad Lon... |
| 20.11.2022 | Acrivon Nets $100M for Protein Tech That Picks Patients for Targeted Cancer Meds | For targeted cancer therapy to work, it’s not enough to identify the right targets to hit with a drug. Just as important is selecting the patients appropriate for a given therapy. Scientists at Acrivon Therapeutics say their approach brings... |
| 04.11.2022 | FDA delays decision for Apellis' eye disease drug after biotech submits updated data | Apellis had secured a priority review for its geographic atrophy program, but it turns out the FDA wants to wait a little bit longer before making a decision.
Regulators have pushed back their decision date for pegcet... |
| 01.11.2022 | Betting on CD47 as others ditch the target, ALX borrows up to $100M to push sole clinical drug forward | At its peak, ALX Oncology $ALXO was trading at $88 per share, riding on the promise of blocking CD47, which cancer cells use to broadcast a “don’t eat me” signal. Today, it’s at under $13. The plunge came after two readouts lat... |
| 25.10.2022 | FDA approves J&J's BCMA-targeted bispecific for multiple myeloma | The FDA on Tuesday granted accelerated approval to Johnson & Johnson’s Tecvayli (teclistamab), a BCMA-directed bispecific antibody, looking to head into an already crowded field of treatments aiming to help tho... |
| 18.10.2022 | Evaluate Forecasts Pharmaceutical Market to be Worth $1.6tn in 2028 | New World Preview report finds strong top-line growth as pricing and patent headwinds build
London, UK and Boston, MA – 18 October 2022: The global pharmaceutical industry is set to see sales grow by an annualised 6% between 2022 and 2028, ... |
| 07.09.2022 | Congress should not compel Medicare to pay for liquid biopsies | When the two Republican senators from Mississippi cosponsor legislation with the two Democratic senators from California, something intriguing must be going on. In fact, there appears to be an outbreak of bipartisanship: 20 Republicans, 25 ... |
| 19.07.2022 | How To Raise The Bar And Overcome Barriers In The Digital Health Space | VP Product-Marketing at Itamar-Medical | Digital Health Expert | Business Growth Mentor | mHealth Israel | G-CMO. |
| 28.06.2022 | Citeline and Norstella Unite to Offer Life Sciences Clients a Full Suite of Commercial and Clinical Solutions | The new organization will help life sciences companies improve strategic decision-making and accelerate the mission of smoothing access to therapy from pipeline to patient
June 28, 2022 – Norstella, an organization that helps life sciences ... |
| 17.06.2022 | Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi | AbbVie just scored another win in its campaign to make Skyrizi one of the top blockbusters in the portfolio while pushing the Big Pharma to the top of the industry list of money makers as their cash cow Humira faces biosimi... |
| 11.05.2022 | Evaluate appoints Matthew Wright as Chief Financial Officer | London, UK and Boston, MA – 11 May 2022 – Evaluate, a leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today announced that it has appointed Matthew Wright as Chief Financial Officer. Wri... |
| 28.04.2022 | Evaluate report signals orphan drug market is niche no more | London, UK – 28 April 2022 – Evaluate, the leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today released the findings of its 2022 Orphan Drug Report.
Evaluate’s data shows that the orph... |
| 25.04.2022 | After 18 years in development, AstraZeneca’s CTLA-4 antibody gets the red carpet treatment at the FDA | After a decade, a second CTLA-4 antibody may finally be on its way to approval.
AstraZeneca announced Monday that the FDA had given priority review to tremelimumab, its long-gestating CTLA-4 antibody, in combinati... |
| 21.04.2022 | Evaluate announces global strategic collaboration with Treehill Partners | London, UK and New York, USA – 21 April 2022 – Evaluate and Treehill Partners today announced that they have entered into a global strategic collaboration to combine Evaluate’s industry leading data analytics and strategic consulting with T... |
| 21.03.2022 | Medtech's top 10 money raisers of 2021 | The medtech industry’s impressive venture funding activity was an anomaly in 2020, when most other sectors were floundering to stay afloat amid the COVID-19 pandemic.
A year later, as businesses around the globe returned to (somewhat) norma... |
| 01.03.2022 | FDA rejects Gilead’s next big HIV drug over glass vial issues | Gilead on Tuesday received a rejection letter for its latest potential first-in-class HIV drug, as the company said the FDA cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with its propos... |
| 18.02.2022 | After selling off Tibsovo and entire cancer pipeline, Agios nets first approval for new 'anchor product' | Agios’ long-term plan is starting to come into focus, as the biotech won its first FDA approval since pivoting away from oncology Thursday.
The FDA approved Agios’ mitapivat in a rare blood disorder known as pyruvate kinase deficiency, whic... |
| 03.02.2022 | Roche regains pre-pandemic sales footing, highlights bursting pipeline — with one key failure | While many pharma fortunes are tied to Covid-19 pandemic peaks and valleys, Roche’s connections are more complicated than most, born out in its 2021 financial reporting.
On one hand, its always top-of-mind diagnostics business, bolstered by... |
| 26.01.2022 | CytoDyn fires embattled CEO as its growing chorus of critics gets louder | The annual exercise where analysts try and predict which drugs will become blockbusters and make the most money tends to highlight the biggest trends in biopharma R&D. 2022 is no exception.
The team at Evaluate Vantage published its pre... |
| 14.01.2022 | After nabbing two AI-generated molecules, AstraZeneca returns to BenevolentAI with new collaboration | Roughly three years ago, AstraZeneca teamed up with London’s BenevolentAI to bring new drugs into its portfolio using the biotech’s AI and machine learning capabilities. Now that the original deal has borne fruit, the two ... |
| 14.01.2022 | Vir expands partnership with Gates Foundation, adding $50M for HIV and malaria antibody research initiative | Just two days after the US bought 600,000 more doses of Vir and GSK’s Covid-19 antibody sotrovimab to guard against Omicron, Vir Biotechnology announced a partnership expansion with the Bill and Melinda Gates Foundation for... |
| 13.01.2022 | Exclusive: Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up... |
| 13.01.2022 | Exclusive: Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years | While 2021 was another big year for biopharma R&D — with the number of IPOs and biotech VC funding eclipsing last year’s impressive amounts — we also saw a few shifts in the market.
First off, biopharma M&A was down 11% from 2020, w... |
| 20.12.2021 | FDA hands AstraZeneca-Amgen broad approval for asthma antibody, clearing blockbuster path | After last year’s Phase III results, there was little question that the FDA would approve Amgen and AstraZeneca’s long-incubating antibody for asthma, barring any manufacturing delays or shocking statistical snafus. ... |
| 13.12.2021 | The top 10 M&A targets in medtech for 2022 | As was to be expected, mergers and acquisitions in the medtech sector slowed down quite a bit in the first half of 2020 as the COVID-19 pandemic boxed out many elective procedures and regular clinic visits. Less expected, however, was the i... |
| 18.11.2021 | Novo Nordisk reaches $3.3B deal to acquire RNAi partner Dicerna Pharma | The field of RNA interference therapies is bustling with activity and Novo Nordisk is the latest company to make a move with an agreement to buy Dicerna Pharmaceuticals for $3.3 billion, a deal that comes as the first therapy from their two... |
| 12.11.2021 | Cardinal Health : Balancing the Needs of Today with the Opportunities of Tomorrow | Balancing the Needs of Today with the Opportunities of Tomorrow
11/10/2021
By Heidi Hunter, President, Cardinal Health Specialty Solutions at Cardinal Health
Lately, I've been talking with colleagues about how to find the balance between fo... |
| 20.10.2021 | Blood tests that can detect cancer are about to hit the market. But experts are still waiting to see if they can upend deadly disease. | A scientist drips blood into a test tube. Serhii Hudak/ Ukrinform/Barcroft Media via Getty Images
Two companies – Exact Sciences and Illumina – plan to have blood tests that detect cancer available by 2022.
They have spent a combined $US10.... |
| 09.09.2021 | Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval? | Looking to scuffle with rare disease giant and now AstraZeneca subsidiary Alexion, little Apellis scored a breakthrough win earlier this summer for its own complement factor inhibitor drug. Apellis, though, always had its... |
| 03.08.2021 | Rare disease drugmakers to Congress: Don't gut the accelerated approval pathway | The controversy over the FDA’s accelerated approval pathway is heating up.
Last week, the FDA’s top oncology official Rick Pazdur said the pathway is “under attack,” largely due to the agency’s recent accelerated ap... |
| 02.08.2021 | Stifling biopharma mergers would kill the innovation economy that generates new therapies | The headlines speak of a biotech boom with news of company launches, oversubscribed private financings, and splashy public offerings. Yet one important milestone in the biotech lifecycle has been conspicuously absent so far this year: merge... |
| 14.07.2021 | AstraZeneca's planned takeover of Alexion clears last regulatory review, deal to close next week | The final regulatory hurdle for AstraZeneca’s mega-merger with Alexion Pharmaceuticals has been cleared, paving the way for the deal to close as soon as next week.
Britain’s financial watchdog, The UK Competition & Ma... |
| 09.07.2021 | Bayer takes SGLT2 hopefuls head on with FDA approval for new kidney disease drug | The FDA on Friday approved Bayer Pharmaceuticals’ chronic kidney disease drug Kerendia (finerenone), the first and only nonsteroidal mineralocorticoid receptor antagonist, offering a new option for CKD. While riv... |
| 18.05.2021 | AbbVie is facing the biggest challenge yet to its best-selling medicine, Humira, as an unlikely Icelandic drugmaker launches a legal fight over 'outrageous' patents and the CEO gets grilled by Congres... | AbbVie CEO Richard A. Gonzalez. AP Photo/Pablo Martinez Monsivais This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
AbbVie, the maker of the mega-blockbuster drug Humira, is faci... |
| 17.05.2021 | The top 10 medtech VC rounds of 2020 | Last year, the COVID-19 pandemic sent countless businesses and entire industries around the world into a death spiral, scrambling to keep their heads above water—but, apparently, nobody told the medtech industry.
In 2020, medtech companies ... |
| 10.05.2021 | Bayer claims another win on its CKD and diabetes hopeful, though the question remains over just how big it is | After earning priority review for a top CKD and diabetes program back in January, Bayer is revealing more data that it hopes will boost its pitch to regulators.
Bayer’s finerenone has passed another Phase III test, the ... |
| 22.03.2021 | Biotech's top 10 money raisers of 2020 | As the coronavirus started to spread in 2020, industry watchers hoped the biopharma sector would pull through and shore up both the IPO market and venture capital investment.
Private investment in the biopharma industry had been trending ge... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | Every company on this list of the top 10 2019 marketing launches — compiled by Evaluate in January — has a lot to prove.
We have Alexion, trying to safeguard its big moneymaking franchise, topping the chart.
Novartis and its new CEO are the... |
| 04.11.2020 | This fintech startup helps investors evaluate the impact of their portfolios on society & planet; raises €12.8M | Over the past decade, impact investing has gained significant momentum as both an investment strategy and an approach to address social and environmental challenges. Impact investing is defined as investments made with the intention to gene... |
| 27.10.2020 | An evolution in early stage gene therapy funding models | A tsunami of curative gene therapies for rare diseases will get through pivotal trials in the coming year or two. This comes on the back of substantial venture-capital finance which has brought these programs out of gestation in academic la... |
| 15.10.2020 | News briefing: Otsuka’s $886M cancer drug is now a 3-time loser in PhIII; Keytruda approved for classical Hodgkin lymphoma | Two years after Otsuka unveiled a flop in their first Phase III trial of guadecitabine as a frontline treatment, they’re back with 2 more pivotal setbacks. But researchers are leaving the door ajar for more studies ahead.
The co... |
| 09.09.2020 | Dabbling in CD47, Pfizer infuses $25M into a biotech player touting positive monotherapy data | Pfizer is following Gilead, AbbVie, Boehringer and a string of biotech upstarts into the CD47 race, lining up its own shots at the “don’t eat me” signal that is shaping up to be the big cancer checkpoint target.
And it’s start... |
| 20.08.2020 | Watch out Bristol Myers, Merck is right on your heels with more positive Keytruda data to take to the FDA | Merck announced positive Phase III results to back yet another indication for cash cow Keytruda — this time as a first-line esophageal cancer treatment in combination with chemotherapy.
Keytruda already has the FDA OK as... |
| 19.08.2020 | Another blow to NASH, disappointing trial results spell end for darkhorse player Albireo | Another NASH program is headed to the scrap heap.
Albireo $ALBO, a Boston biotech that took an unconventional route to treating the fatty liver disease, announced yesterday that they were ending NASH development after ... |
| 14.08.2020 | TRIFAST PLC
Trifast : 2020 Annual Report | Annual Report for the year ended 31 March 2020
Our fastenings enable innovation today
to build a better tomorrow
Welcome to the
Annual Report
Our purpose
To provide Trusted Reliability at every turn to our customers in global industry, empo... |
| 06.04.2020 | Top biotech money raisers of 2019 | At first glance, venture investment for biotech slumped in 2019. By the raw numbers, 2019 lost on every metric compared with 2018. Total investment dollars dropped by $4 billion, to $13.9 billion in 2019 from $17.9 billion in 2018, and the ... |
| 01.04.2020 | Evaluate Acquires Black Swan Analysis | Evaluate Ltd., a London, UK-based provider of commercial intelligence and predictive analytics to the pharmaceutical industry, completed an acquisition of Black Swan Analysis, a London, UK-based consultancy specializing in asset valuations ... |
| 13.03.2020 | Mending the broken social contract for pharmaceutical pricing and innovation | The biopharmaceutical industry is under unprecedented assault by the public and politicians. Hostility over launch prices for new drugs and post-launch price increases is broad and bipartisan, reflected in increasingly draconian legislative... |
| 03.09.2019 | ESC Congress 2019: Biotronik beats Abbott at target lesion failure | Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial.
The randomized, controlled BioSTEMI trial was the first direct ... |
| 03.09.2019 | Armed with promising alopecia PhII, Concert edges forward with modified JAK inhibitor — but safety will still be key | Concert Pharma has scored a fresh round of positive Phase II data for its JAK inhibitor amid an ongoing rivalry with Pfizer, paving the way for a late-stage showdown in alopecia areata. It’s also cautiously staking a claim... |
| 31.07.2019 | Report: “Unglamorous” medtech outshines biopharma in 2019 | Medtech merger and acquisition deal announcements slowed in the first half of 2019, but the industry got a boost from Verily’s $1 billion round of funding — the largest ever for a medtech firm.
The Verily round was twice the size of the big... |
| 24.05.2019 | Why precision medicines for oncology demands precision engagement | Life sciences companies are overwhelmed with the volume of information and data available as they aim to keep oncologists up to date on new therapies, while also bring patient-reported information back to their organizations to inform ongoi... |
| 15.05.2019 | Biotech's top 10 money raisers of 2018 | If 2017 was a banner year for biotech venture capital, 2018 blew it out of the water. Last year, private biotech companies reeled in a grand total of $16.8 billion, eclipsing 2017’s then-record $12.1 billion by 39%. And it wasn’t just the t... |
| 01.04.2019 | Atlas wraps Arteaus story with $260M royalty sale as Emgality sales inches upward | Six months after Eli Lilly notched a second-runner-up approval for its CGRP migraine drug Emgality, the Atlas-founded biotech that brought it over the proof-of-concept gate five years ago has sold all its royalty interest fo... |
| 22.01.2019 | Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing | Nina Kjellson was just two years out of college, working as a research associate at Oracle Partners, a hedge fund in New York, when a cabbie gave her a stock tip. There was a company in New Jersey, he told her, trying to resurrect thalidomi... |
| 14.11.2018 | Exclusive: Digital health company HeartFlow gets Japanese reimbursement approval for cardiac diagnostic tech | The company claims that using its technology allows doctors to make more cost-efficient and safer clinical care decisions for people with suspected coronary artery disease (CAD) by avoiding the risk factors like bleeding, bruising and infec... |
| 25.09.2018 | Carillon hits the right note | Vantage
by Elizabeth Cairns
25 September 2018
Abbott’s MitraClip is suddenly hot property after the highly positive Coapt results presented this weekend, and now another mitral valve repair device has also hit in a study – though this time ... |
| 05.09.2018 | What's up at Immunocore?; Pfizer nabs a key 'breakthrough'; Adaptimmune raises $100M | → What’s up at Immunocore? Vantage is reporting that Immunocore’s chief strategy officer Kevin Pojasek is out, marking the latest in a long line of C-suite departure for the company. CEO Eliot Forster was first to depart,... |
| 10.08.2017 | In an era of mega-rounds, Roivant Sciences still makes a splash with $1.1B haul | Announced Wednesday, the company said the new capital injection is designed to “accelerate the launch of new subsidiaries within and beyond the biopharmaceutical industry.”
That means expanding the Vant empire, which includes Axovant, Myova... |
| 29.10.2016 | Cognitive assessment startup using games to evaluate brain function raises $3M | BrainCheck is a participant in the Texas Medical Center Accelerator in Houston. The company’s backers include angel investors such as Brett Giroir, a strategic adviser to the accelerator who took part in the seed round, according to TechCru... |
| - | FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades | The Food and Drug Administration approved Vertex Pharmaceuticals’ non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction.
It’s a milestone after a long history of unsuccessful efforts to devel... |
| - | Evaluate Vision: harnessing data science to quantify technical and regulatory success | created February 2020
London’s Evaluate absorbs, aggregates, structures, normalises and enriches the data produced by the pharmaceutical industries.
Combining his huge bank of information with data science, machine learning and 25 years o... |
| - | Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain | Vertex Pharmaceuticals said its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in late-stage trials.
The drug, known as VX-548, did not work better than a pop... |
| - | The DNA of better health care for rare diseases | Less than two decades into the genomic era in health care, our knowledge about the connections between DNA and human health continues to explode, from the genetic underpinnings of disease to how to use genetics to identify what therapy is b... |
| - | Here are the 18 investors set to shape biotech in 2022 | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider analyzed more than 90 IPOs to find the top venture-capital firms that led biotech in 2021.
Arch, Novo Holdings, and Flagship Pionee... |
| - | In an era of mega-rounds, Roivant Sciences still makes a splash with $1.1B haul | The top drug recycling engine in the game, Roivant Sciences, has raised a massive $1.1 billion equity investment round led by Softbank Vision Fund, with support from existing shareholders.
Announced Wednesday, the company said the new capit... |
| - | Microbiome biotech Kaleido Biosciences shutters amid cash crunch, drug setbacks | Microbiome therapies could have a big year as several biotech companies are preparing for key regulatory and clinical benchmarks in 2022. Kaleido Biosciences will not be among them. The company is shutting down, a last resort move that foll... |
| - | Cognitive assessment startup using games to evaluate brain function raises $3M | BrainCheck cognitive assessment test
BrainCheck, a Houston-based health IT company that digitized cognitive assessment tests to assess athletes for signs of a concussion, has raised $3 million, according to a news release. The business plan... |
| - | Why precision medicines for oncology demands precision engagement | The speed of scientific breakthroughs in precision medicine is leading to groundbreaking treatments, particularly in oncology and rare diseases. More than 85 percent of the oncology market is now focused on targeted therapies and the number... |
| - | Novo Nordisk reaches $3.3B deal to acquire RNAi partner Dicerna Pharma | The field of RNA interference therapies is bustling with activity and Novo Nordisk is the latest company to make a move with an agreement to buy Dicerna Pharmaceuticals for $3.3 billion, a deal that comes as the first therapy from their two... |
| - | Exclusive: Digital health company HeartFlow gets Japanese reimbursement approval for cardiac diagnostic tech | Redwood City, California-based digital health company HeartFlow has reached a major milestone in its international expansion efforts after Japan’s health ministry approved the reimbursement of its technology to analyze arterial blood flow.
... |
